• About
  • Subscribe
  • Advertise
  • Contact
Thursday, February 12, 2026
Newsletter
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
Home Local

Hoya releases three-year follow-up study of myopia spectacle lens

by Myles Hume
April 27, 2021
in Business, Company updates & acquisitions, International, Local, News, Research
Reading Time: 3 mins read
A A
Previous two-year data showed the lens reduced myopia progression by 60% on average.

Previous two-year data showed the lens reduced myopia progression by 60% on average.

Share on FacebookShare on Twitter

New data published in the British Journal of Ophthalmology (BJO) has shown Hoya’s MiyoSmart lens continued to slow myopia progression in children after three years, while patients who switched from single vision lenses had a significant slowdown in their condition.

The ophthalmic lens maker – which released its myopia control spectacle lens in Australia last September – announced the results of a three-year follow up clinical study on its lens incoporating Defocus Incorporated Multiple Segments (D.I.M.S) Technology.

The study, published last month, was conducted by the Centre for Myopia Research at The Hong Kong Polytechnic University and follows up on a two-year study that previously demonstrated children aged eight to 13 wearing its defocus lenses had 60% less myopia progression compared with those wearing single-vision spectacles.

The three-year follow-up study involved 120 children in Asia, comprising 65 from the original MiyoSmart lens group who took part in the previous study and 55 children who moved from a single-vision lens for two years to the MiyoSmart lens in the third year.

At the end of the third year, results in the original MiyoSmart group showed that slowing in myopia progression over time was sustained. Meanwhile, Hoya reported the group that moved from single-vision to MiyoSmart lenses showed “a significant and immediate slowdown” in the progression of their myopia.

Hoya’s MiyoSmart lens incporates Defocus Incorporated Multiple Segments (D.I.M.S) Technology.

Specifically, over three years, spherical equivalent refraction (SER) and axial length (AL) changes in the MiyoSmart group were −0.52±0.69D and 0.31±0.26 mm. These changes were not considered statistically significant over time.

The SER (−0.04±0.38D) and AL (0.08±0.12 mm) changes in those who switched from single vision to MiyoSmart in the third year were less compared with the first year (mean difference=0.45±0.30D, 0.21±0.11 mm, p<0.001) and second year (0.34±0.30D, 0.12±0.10 mm, p<0.001).

“These findings provided further evidence that D.I.M.S lenses slowed myopia progression and axial elongation in children,” the authors noted.

“The optimal age at which treatment should commence is still to be determined and further monitoring is required to ascertain the treatment effect over a longer period. We also plan to follow up on those children who discontinued wearing the DIMS lenses to determine if rebound occurs.”

Hoya Vision Care chief technology officer Mr Griff Altmann said the results of the three-year follow-up study are positive and provide evidence that the lens continues to slow myopia progression in children, including “the impressive results when switching from a single vision lens”.

“As myopia in children is on the rise globally, Hoya Vision Care is proud to be a leader in developing a safe, easy and effective way to manage the growing problem,” he said.

Hoya developed the MiyoSmart lens with The Hong Kong Polytechnic University.

The three-year study data published in the BJO can be found here.

More reading

Have lockdowns and screen time escalated Australia’s myopia problem?

Hoya Lens Australia and DFV form myopia alliance

Hoya launches defocus myopia lens for children

 

Tags: AustraliaBritish Journal of OphthalmologyCentre for Myopia ResearchHoyalens myopiamiyosmartprogressionslowdownThe Hong Kong Polytechnic Universit

Related Posts

The retrospective study evaluated 58 children who had been born prematurely and followed for at least 12 months. Image: pop_thailand/stock.adobe.com

Study suggests HALT lenses may slow myopia in children born preterm

by Staff Writer
February 12, 2026

A new study has found that spectacle lenses using Highly Aspherical Lenslet Target (HALT) technology may slow the progression of...

The study looked at the impact of bacteria found in the eye. Image: Sokie/stock.adobe.com.

Study: Bacterium in retina linked to Alzheimer’s disease, cognitive decline

by Staff Writer
February 12, 2026

Researchers at Cedars-Sinai Medical Center in the US have established a link between bacterium in the retina and cognitive decline...

The system integrates a built-in PC and tiltable touch-screen display in a compact footprint. Image: BOC Instruments

BOC Instruments introduces automated AutoFusion OCT device

by Staff Writer
February 11, 2026

BOC Instruments has announced the release of a new Optovue optical coherence tomography (OCT) system, the AutoFusion, which combines OCT...

Join our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

Insight has been the leading industry publication in Australia for more than 40 years. This longevity is largely due to our ability to consistently deliver accurate and independent news relevant to all ophthalmic professionals and their supporting industry.

Subscribe to our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

About Insight

  • About
  • Advertise
  • Subscribe
  • Contact
  • Terms & Conditions
  • Privacy Collection Notice
  • Privacy Policy

Popular Topics

  • Business
  • Feature
  • Research
  • Technology
  • Therapies
  • Classifieds

© 2026 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited

No Results
View All Results
NEWSLETTER
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
  • About Us
  • Advertise with Insight
  • Subscribe
  • Contact Insight

© 2026 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited